Canada Markets closed

Numinus Wellness Inc. (NUMI.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.8300-0.0100 (-1.19%)
At close: 3:59PM EDT
Sign in to post a message.
  • N
    Hopefully the NCT increases our Q3 revenue!
  • L
    Numi! I'm not giving up one you...
  • N
    Wyckoff’s Accumulation, spring coming soon
  • N
    One buyer from Scotia bought all those shares
  • Q
    Qwerty McMullen
    Payton has mentioned an exchange upgrade in the near future to NASDAQ in the states. It seems there is a big jump to list on the non-venture TSX. Does anyone see NUMI eventually making a move to list on the NEO exchange along side of Cybin?
  • J
    Remember the golden rule
  • K
    I won't tell anyone what to do with their money or stocks. What I would like to do is remind people of some of the bullets from the last earnings report and these wise words "The stock market is a device for transferring money from the impatient to the patient.” - W. Buffett. The bullets:

    - Cash balance of $63.2 million as at May 31, 2021.

    - Generated revenues of $562,076 and $1,022,771 for the three and nine months, respectively, ended May 31, 2021, compared to $216,244 and $610,148 for the same periods, respectively, ended May 31, 2020, for a total year-over-year increase of 160% and 68%, respectively.

    - Announced 7,500 square foot expansion of Numinus Bioscience’s research laboratory.

    - Announced acquisition of the Neurology Center of Toronto (NCT) for a total of $1.1 million, allowing for the planned expansion of NCT into a comprehensive neurologic care centre specialized in psychedelic neurology.

    - Announced a Phase 1 clinical trial to assess the safety and efficacy of a Psilocybe extract developed at Numinus Bioscience.

    - Filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a rapid production process containing psychoactive compounds, with the first proprietary extract from Psilocybe cubensis containing psilocybin, other indole alkaloids and additional beneficial compounds.

    - Received amendments to the Health Canada licence under Numinus Bioscience, including the addition of Ketamine and LSD to the list of permitted research substances (alongside DMT, MDMA, Mescaline, Psilocin, Psilocybin) and expanded ability to produce finished products for research and supply of other groups. These changes expand the lab’s capabilities and position as an industry manufacturer and supplier.

    Best of luck with your investments!
  • P
    which party benefits numinus the best? ( election)
  • S
    Why is this stock under performing?
  • M
    Back on the NUMI train! Let's go!!??!
  • p
    Yoooo Payton wake this thing up
  • P
    Gereral markets are down and for Numi and other psychedelics in Canada there is the added risk of the election outcome today. Conservatives win and its less likely that mushroom treatments will be approved anytime soon. Progressives win and its more likely. Right now conservatives have a slight edge over progressives, so that could also be a conributing factor for the steep decline in the last few days
  • P
    Buying more at $0.74 was the right choice.
  • m
    This is due for another spike IMO.
  • O
    I bought 10 shares made it go through the roof
  • M
    Maybe insider info on the election because many other shroom stocks saw a big jump as well. Just an idea
  • J
    It’s like all prior knowledge and news has gone out the window and everyone forgot what this company is worth and where it can go .
  • T
    The Hulkster
    All of you impatient sellers will have fomo when news is announced and the stock goes up 50% in one day haha
  • Y
    Nice! About time that we see the NCT acquisition being finalized.